Represented Emageon Inc., a publicly traded provider of healthcare-related, dynamic user interface technologies and software for managing medical images for healthcare entities, in connection with patent and licensing matters. The firm analyzed a number of third party patents to provide this client with clearance and patentability opinions. The analysis focused on determining whether there were any patents that would limit Emageon’s proposed products or that would impact Emageon’s ability to obtain patent protection. Several years later, a third party contacted Emageon and suggested that Emageon needed to license for one of the third party’s patents. Based on the analysis of the patents in connection with the clearance and patentability opinions, the firm was able to identify patents that would invalidate or substantially limit the scope of this third party’s patent, and were able to successfully negotiate without the need for a license. The client’s application related to this technology has since been allowed in the United States.

Experience Center

Match our Experience to Your Needs

Experience Highlights

Antitrust review of merger between pharmaceutical companies
Represented a pharmaceutical company before FTC regarding antitrust review of merger with another pharmaceutical company and negotiation of consent more
Merger of Pro Brand International Inc.
Represented Pro Brand International, Inc., in its merger with special purpose acquisition company Granahan McCourt Acquisition Corp. (AMEX: GHN). Pro more
Global trademark licensing and portfolio management and enforcement for JA Apparel Corp. (dba Joseph Abboud)
The firm serves as global trademark and licensing counsel to JA Apparel Corp., a $400 million worldwide lifestyle apparel, home furnishings and more
Counsel to the Massachusetts Convention Center Authority Regarding US $1 Billion Massachusetts Convention and Exhibition Center in Boston, Massachusetts
Represented the public owner in connection with the development, construction, delivery and claims resolution of its US $1 Billion Convention & more